Researchers work to create a COVID-19 viral epitope map
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
List view / Grid view
The team used data from SARS-CoV to identify possible viral epitopes that vaccines could include to stimulate an immune response.
Researchers have identified that copper ions and their protein transporters, such as Atox1, are key to cancer cell movement and could be targeted by therapies.
Researchers have created a new technical resource atlas which maps the 15 distinct cell types involved in muscle repair for disease and therapy research.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
A new study has revealed five factors and proteins that hepatitis B infection needs for replication of its DNA, providing insight into the disease.
An enzyme that adds a cell-signalling code to proteins has been identified by researchers, who say their discovery could aid in the development of cancer therapies.
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
Researchers have used cryogenic electron microscopy to show that coronaviruses enter human cells through an interaction with angiotensin-converting enzyme 2 (ACE2).
A new method for weighing proteins at the atom level, called individual ion mass spectrometry, has been developed by American researchers.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
Researchers have revealed that the WDR74 protein plays a key role in lung cancer and melanoma, including metastasis, indicating it may be a potential drug target.
Scientists in Japan have identified an important protein that can impact the course of cancer and its fate in the human body.
A research team has shown that a key difference between neurogenic and non-neurogenic tissues is cross-linking proteins causing stiffness, a discovery that could be used to create new brain injury therapies.
A study has shown that targeting the proteins mtp53 and PARP in triple negative breast cancer could inhibit tumour growth and provide a new treatment option.